- Coordinator
- Escala Medical Ltd, Israel
- Runs
- 1 October 2023 to 30 September 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €5.1m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190143220
What the project is doing
In the project's own words, from its summary on CORDIS.
Pelvic Organ Prolapse (POP) affects nearly 50% of women over 40 years old globally. 89% of the cases seek treatment for symptomatic early stage prolapse. Despite the high prevalence and the progression of POP over time, patients currently cannot be offered a repair solution until the condition worsens enough for surgical intervention. However, the surgical interventions of prolapse have several side effects like prolonged recovery, pelvic pain and relapses of POP.
Escala Medical has developed a minimally invasive and incision-free repair intervention for early-stage POP repair - Apyx. Apyx is the first medical device for treating early stage prolapse, regaining quality of life and prevention of prolapse deterioration for the vast majority, currently un-addressed, POP sufferers. The EIC project will finalize the development of Apyx, conduct clinical trials, and support scale-up and commercialization activities.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Escala Medical Ltd | Misgrav | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI